Blazar is a digital platform that utilizes deep learning and machine learning to analyze clinical patient data and predict responses to immunotherapy in solid tumor patients through biomarker identification. The platform addresses the challenge of accurately assessing treatment efficacy and patient outcomes, ultimately enhancing patient quality of life and lifespan.
Funding
Funding not disclosed
EFPAFounders
Product
Problem
Predicting patient response to immunotherapy in solid tumors is challenging due to complex interactions between tumor biology, the immune system, and patient-specific factors. Traditional methods for assessing treatment efficacy often lack the precision needed to stratify patients and personalize therapeutic strategies. This uncertainty can lead to delayed or inappropriate treatment decisions, impacting patient outcomes and quality of life.
Solution
Blazar is an AI-powered platform that analyzes digitalized clinical patient data to predict individual responses to immunotherapy. By integrating clinical know-how, machine learning, and statistical methodologies, Blazar identifies and validates combinations of biomarkers to stratify patients based on their likelihood of response. The platform provides clinicians with tools to understand the tumor microenvironment, tumor cell biology, patient genetics, and immune system status, offering potential explanations for non-response. Blazar aims to improve patient outcomes by enabling more informed and personalized treatment decisions.
Target Audience
The primary users are oncologists, pathologists, and researchers involved in cancer treatment and immunotherapy, seeking to improve patient stratification and treatment outcomes.
Features
- Deep learning and machine learning algorithms for biomarker identification and validation
- Analysis of clinical patient data, including tumor microenvironment, cell biology, and patient genetics
- Prediction of response and resistance to immunotherapies in solid tumor patients
- Software tools for analysis and annotation of patient biopsy and tumor resection
- Biomarker discovery to predict response to cancer therapies